Co-Diagnostics, Inc. Announces Mosquito Vector Control Training Course in the Dominican Republic

Trainings will be conducted for staff and customers of
Laboratorios Franja, including demonstrations of Company’s vector
control products

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics
company with a unique, patented platform for the development of
molecular diagnostic tests, announced today that their distributor in
the Dominican Republic is hosting a workshop on techniques for applying
molecular diagnostics to identify disease-carrying mosquitos. The
trainings will be conducted by a Co-Diagnostics representative and will
include demonstrations of the Company’s polymerase chain reaction (PCR)
malaria and ZDC (multiplex Zika-dengue-chikungunya) tests.

Laboratorios Franja S.R.L. is the exclusive distributor of the Company’s
products in the Dominican Republic, a country of nearly 12 million
people, and will be hosting the demonstrations for its customers and
other bioanalysts, veterinarians, and pest control companies. All
demonstrations will be conducted on the Company’s CoDx Box™, a magnetic
induction thermocycler with software optimized to run Co-Diagnostics’
PCR products. The Company’s assays for malaria and ZDC can be applied to
testing mosquito populations to track the presence of infectious
diseases in urban and rural areas alike. Vector (the term used to
describe an organism that transmits infectious diseases) control and
mosquito abatement play a vital role in preventing outbreaks and the
spread of mosquito-borne diseases.

Mr. Cameron Gundry, Company Director of Commercialization for Latin
America, remarked, “A very clear and distinct need exists for vector
control and mosquito abatement in this region. Laboratorios Franja has
been a valuable partner in identifying and engaging the customers who
would benefit from accurate, affordable molecular diagnostics for these
vector-based applications, and this workshop represents several months
of outreach and planning.

“Malaria, a mosquito-borne parasite which infects over 2 million people
every year and kills nearly 400,000, is both preventable and treatable
with early detection, including among the mosquito populations before
outbreaks occur. Zika, dengue, and chikungunya are closely-related
viruses but important to distinguish between and, like malaria, are more
dangerous among the children, the elderly, and pregnant women. We
anticipate the interest generated by this workshop will help to further
our commercialization efforts in the DR, in a mutually beneficial
relationship with the mosquito abatement industry and the public good
they provide.”

Laboratorios Franja, an ISO 9001:2015 certified company, has been
assisting the Company with all local registration requirements needed to
allow import and sale of its products in the Dominican Republic for
diagnostic, Research Use, and vector control applications. Laboratories,
local health ministries, and other companies interested in using the
Company’s technology to improve their vector control efforts should
contact Laboratorios Franja at info@laboratoriosfranja.com.
More information about the workshop can be found on the event’s
brochure, seen here.

About Laboratorios Franja S.R.L.:

Laboratorios Franja is one of the most complete and efficient
microbiology laboratories in Santo Domingo, offering distribution and
sales of microbiology chemistry (cosmetics, medical equipment and
cleaning) products, and food quality/safety, environmental microbiology
and physical water chemistry analyses. Laboratorios Franja also markets
and distributes high quality culture media, and related state-of-the-art
technology. Owned and operated by Frank Reyes, the distributor has a
highly qualified team of medical, lab staff and sales staff, and can be
found online at www.laboratoriosfranja.com.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company with a proprietary diagnostic testing technology and development
platform that intends to manufacture and sell reagents used for
diagnostic tests that function via the detection and/or analysis of
nucleic acid molecules (DNA or RNA), and license the use of its platform
to other non-competing developers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking
statements can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar expressions,
or the negative of these words. Such forward-looking statements are
based on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements regarding
the (i) use of funding proceeds, (ii) expansion of product distribution,
(iii) acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s products
and markets, (vi) increased sales in the near-term, (vii) flexibility in
managing the Company’s balance sheet, (viii) anticipation of business
expansion, and (ix) benefits in research and worldwide accessibility of
the CoPrimer technology and its cost-saving and scientific advantages.
Forward-looking statements are subject to inherent uncertainties, risks
and changes in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue reliance
on any forward-looking statements. The Company does not undertake any
obligation to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by applicable
securities laws.

Contacts

Denny Crockett
Co-Diagnostics Sales Representative
801-438-1036
d.crockett@codiagnostics.com